JP2021526858A5 - - Google Patents

Info

Publication number
JP2021526858A5
JP2021526858A5 JP2021518052A JP2021518052A JP2021526858A5 JP 2021526858 A5 JP2021526858 A5 JP 2021526858A5 JP 2021518052 A JP2021518052 A JP 2021518052A JP 2021518052 A JP2021518052 A JP 2021518052A JP 2021526858 A5 JP2021526858 A5 JP 2021526858A5
Authority
JP
Japan
Prior art keywords
rna
composition according
binding polypeptide
polypeptide
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526858A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/036021 external-priority patent/WO2019236982A1/en
Publication of JP2021526858A publication Critical patent/JP2021526858A/ja
Publication of JP2021526858A5 publication Critical patent/JP2021526858A5/ja
Pending legal-status Critical Current

Links

JP2021518052A 2018-06-08 2019-06-07 Rna標的化融合タンパク質組成物および使用方法 Pending JP2021526858A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682271P 2018-06-08 2018-06-08
US62/682,271 2018-06-08
PCT/US2019/036021 WO2019236982A1 (en) 2018-06-08 2019-06-07 Rna-targeting fusion protein compositions and methods for use

Publications (2)

Publication Number Publication Date
JP2021526858A JP2021526858A (ja) 2021-10-11
JP2021526858A5 true JP2021526858A5 (cg-RX-API-DMAC7.html) 2022-06-15

Family

ID=68769584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518052A Pending JP2021526858A (ja) 2018-06-08 2019-06-07 Rna標的化融合タンパク質組成物および使用方法

Country Status (9)

Country Link
US (3) US20200071718A1 (cg-RX-API-DMAC7.html)
EP (1) EP3802812A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021526858A (cg-RX-API-DMAC7.html)
KR (1) KR20210058806A (cg-RX-API-DMAC7.html)
CN (1) CN112930395A (cg-RX-API-DMAC7.html)
AU (1) AU2019280990A1 (cg-RX-API-DMAC7.html)
CA (1) CA3102779A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012004SA (cg-RX-API-DMAC7.html)
WO (1) WO2019236982A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160052A2 (en) 2010-06-18 2011-12-22 The University Of North Carolina At Chapel Hill Methods and compositions for sequence specific rna endonucleases
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
CN113544267B (zh) 2019-01-14 2025-04-18 罗切斯特大学 使用CRISPR-Cas进行靶向核RNA裂解和聚腺苷酸化
WO2021016453A1 (en) * 2019-07-23 2021-01-28 University Of Rochester Targeted rna cleavage with crispr-cas
US11572565B2 (en) 2020-07-21 2023-02-07 Trustees Of Boston University Inducible control of gene expression
CN112126645B (zh) * 2020-09-11 2021-06-01 广州吉赛生物科技股份有限公司 一种环形rna敲低方法及其应用
CN112430597A (zh) * 2020-11-24 2021-03-02 深圳市瑞吉生物科技有限公司 一种使目的基因沉默的CasRx制剂及其应用
US20240000972A1 (en) * 2020-12-01 2024-01-04 Locanabio, Inc. Rna-targeting compositions and methods for treating cag repeat diseases
CN117320741A (zh) * 2020-12-01 2023-12-29 洛卡纳生物股份有限公司 用于治疗cag重复疾病的靶向rna的组合物和方法
WO2022119979A1 (en) * 2020-12-01 2022-06-09 Locanabio, Inc. Rna-targeting compositions and methods for treating myotonic dystrophy type 1
GB202105455D0 (en) 2021-04-16 2021-06-02 Ucl Business Ltd Composition
US20250320258A1 (en) * 2021-06-02 2025-10-16 The Regents Of The University Of California Rna recognition complex and uses thereof
JP2025500531A (ja) * 2021-12-27 2025-01-09 グラセル バイオテクノロジーズ(シャンハイ)カンパニー,リミテッド 細胞改変のための系及び方法
CN114835776B (zh) * 2022-04-08 2023-09-01 陕西师范大学 一种靶向Smad4/PELO相互作用的抵抗肿瘤转移小分子多肽及应用
CN116949011A (zh) * 2022-04-26 2023-10-27 中国科学院动物研究所 经分离的Cas13蛋白、基于它的基因编辑系统及其用途
WO2024092230A2 (en) * 2022-10-28 2024-05-02 The Regents Of The University Of California Recombinant enhanced antiviral restrictors
CN115820603B (zh) * 2022-11-15 2024-07-05 吉林大学 一种基于dCasRx-NSUN6单基因特异性M5C修饰编辑方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182063A3 (en) * 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulation of EIF4E expression
US20110002981A1 (en) * 2006-12-20 2011-01-06 Kolattukudy Pappachan E MCPIP Protection Against Cardiac Dysfunction
WO2011160052A2 (en) * 2010-06-18 2011-12-22 The University Of North Carolina At Chapel Hill Methods and compositions for sequence specific rna endonucleases
US9580714B2 (en) 2010-11-24 2017-02-28 The University Of Western Australia Peptides for the specific binding of RNA targets
ES2751126T3 (es) 2011-10-21 2020-03-30 Univ Kyushu Nat Univ Corp Método de diseño para proteína de unión a ARN usando motivo de PPR, y uso del mismo
JP6793547B2 (ja) * 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
WO2015138855A1 (en) * 2014-03-14 2015-09-17 The Regents Of The University Of California Vectors and methods for fungal genome engineering by crispr-cas9
US10330674B2 (en) 2015-01-13 2019-06-25 Massachusetts Institute Of Technology Pumilio domain-based modular protein architecture for RNA binding
US10392607B2 (en) 2015-06-03 2019-08-27 The Regents Of The University Of California Cas9 variants and methods of use thereof
AU2016359629B2 (en) * 2015-11-23 2023-03-09 Ranjan BATRA Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
CN109152808A (zh) * 2016-04-29 2019-01-04 生物辐射实验室股份有限公司 用于核酸序列的特异性靶向的二聚蛋白质
US12180499B2 (en) 2016-10-31 2024-12-31 University Of Florida Research Foundation, Inc. Compositions and methods for impeding transcription of expanded microsatellite repeats
CN110959039B (zh) 2017-03-15 2025-03-14 博德研究所 新型cas13b直向同源物crispr酶和系统
KR102357045B1 (ko) 2017-03-31 2022-01-28 뉴로디아그노스틱스 엘엘씨 알츠하이머 질환에 대한 림프구-기반 형태계측 시험
US10392616B2 (en) 2017-06-30 2019-08-27 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
US10476825B2 (en) 2017-08-22 2019-11-12 Salk Institue for Biological Studies RNA targeting methods and compositions
JP2021526860A (ja) 2018-06-08 2021-10-11 ロックアネイビオ, インコーポレイテッド 適応免疫をモジュレートするための組成物および方法
EP3841116A4 (en) * 2018-08-24 2022-05-25 Locanabio, Inc. FASL IMMUNOMODULATING GENE THERAPY COMPOSITIONS AND METHODS OF USE

Similar Documents

Publication Publication Date Title
JP7698828B2 (ja) Rnaを編集する方法および組成物
JP7672445B2 (ja) CasZ組成物及び使用方法
JP7252328B2 (ja) Rnaを編集する方法および組成物
JP2025026840A5 (cg-RX-API-DMAC7.html)
CN111094561B (zh) 靶特异性crispr变体
AU2025263805A1 (en) Novel crispr enzymes and systems
US11111506B2 (en) Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
JP2026083211A (ja) 真核生物の遺伝子編集のためのレンチウイルスベースのベクターならびに関連システムおよび方法
CN111757889A (zh) 新型CRISPR/Cas12f酶和系统
JP2023027277A (ja) Rna誘導型核酸修飾酵素及びその使用方法
JP2022519507A5 (cg-RX-API-DMAC7.html)
JP2021518139A5 (cg-RX-API-DMAC7.html)
CN109072235B (zh) 通过核递送crispr/cas9追踪并操纵细胞rna
CN113811607A (zh) CRISPR-Cas效应子多肽和其使用方法
JP2021526860A5 (cg-RX-API-DMAC7.html)
JP2020022459A5 (cg-RX-API-DMAC7.html)
KR20160089530A (ko) Hbv 및 바이러스 질병 및 질환을 위한 crispr­cas 시스템 및 조성물의 전달,용도 및 치료적 적용
CN114040971A (zh) CRISPR-Cas效应子多肽及其使用方法
US20260022359A1 (en) Compositions and methods for nucleic acid modifications
JP2021533812A5 (cg-RX-API-DMAC7.html)
KR102626503B1 (ko) 뉴클레오타이드 표적 인식을 이용한 표적 서열 특이적 개변 기술
KR20240164823A (ko) 게놈 편집의 조성물및 방법
JP2021536250A5 (cg-RX-API-DMAC7.html)
JP2020533411A5 (cg-RX-API-DMAC7.html)
CN107151677A (zh) 基于CRISPR/Cas9多基因敲除低转染效率细胞系的新方法